Get the Stockscreener App
3.53
0.57%
0.02
After Hours:
3.50
-0.03
-0.85%
Polypid Ltd stock is traded at $3.53, with a volume of 59,247.
It is up +0.57% in the last 24 hours and down -2.49% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.51
Open:
$3.55
24h Volume:
59,247
Relative Volume:
0.12
Market Cap:
$56.12M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.1795
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
+3.22%
1M Performance:
-2.49%
6M Performance:
+21.72%
1Y Performance:
-0.56%
1-Day Range:
$3.45
$3.55
1-Week Range:
$3.2614
$3.59
52-Week Range:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.53 | 54.85M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
Short interest data insights for PolyPid Ltd.Earnings Overview Summary & Advanced Technical Signal Analysis - Newser
What high frequency data says about PolyPid Ltd.July 2025 Short Interest & Weekly Return Optimization Alerts - Newser
Can technical indicators confirm PolyPid Ltd.’s reversalGDP Growth & Safe Capital Growth Tips - Newser
What’s the recovery path for long term holders of PolyPid Ltd.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Forecasting PolyPid Ltd. price range with options dataJuly 2025 Earnings & Daily Market Momentum Tracking - Newser
Does PolyPid Ltd. fit your quant trading model2025 Winners & Losers & Free Community Supported Trade Ideas - Newser
Live market analysis of PolyPid Ltd.Gap Down & Free Real-Time Volume Trigger Notifications - Newser
Does PolyPid Ltd. qualify in momentum factor screeningJuly 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - Newser
Will breakout in PolyPid Ltd. lead to full recoveryAnalyst Downgrade & Risk Controlled Daily Plans - Newser
Machine Learning Models Forecast PolyPid Ltd. UptickWeekly Market Report & Risk Controlled Stock Pick Alerts - newsyoung.net
Risk adjusted return profile for PolyPid Ltd. analyzedPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser
How institutional ownership impacts PolyPid Ltd. stockVolume Spike & Daily Momentum Trading Reports - Newser
Roth Capital Has Negative Outlook for PolyPid Q3 Earnings - Defense World
Will PolyPid Ltd. benefit from macro trendsTrade Volume Summary & Free Fast Entry Momentum Trade Alerts - Newser
Detecting price anomalies in PolyPid Ltd. with AIGap Down & Comprehensive Market Scan Insights - Newser
Pattern recognition hints at PolyPid Ltd. upsidePortfolio Gains Report & Proven Capital Preservation Methods - Newser
Sector ETF performance correlation with PolyPid Ltd.July 2025 Short Interest & Fast Moving Stock Watchlists - Newser
Can PolyPid Ltd. lead its sector in growthWeekly Earnings Recap & Target Return Focused Picks - classian.co.kr
Is PolyPid Ltd. forming a breakout patternQuarterly Profit Summary & Daily Stock Momentum Reports - classian.co.kr
Custom watchlist performance reports with PolyPid Ltd.2025 Top Decliners & Daily Risk Controlled Trade Plans - Newser
Developing predictive dashboards with PolyPid Ltd. dataMarket Sentiment Review & Long-Term Safe Return Strategies - Newser
PolyPid Ltd. stock volume spike explainedWeekly Market Outlook & Free Weekly Watchlist of Top Performers - Newser
Will PolyPid Ltd. Sustain Its Chart BreakoutJuly 2025 Big Picture & Reliable Price Breakout Signals - newsyoung.net
PolyPid (NASDAQ:PYPD) Rating Lowered to “Sell” at Wall Street Zen - Defense World
HC Wainwright Has Negative Outlook for PolyPid Q3 Earnings - Defense World
PolyPid Ltd. Company Revenue and Profit Trends: A Deep DiveAnalyst Upgrade & Safe Entry Zone Tips - Newser
Why PolyPid Ltd. stock attracts strong analyst attentionSell Signal & Safe Entry Trade Reports - Newser
Is PolyPid Ltd. a candidate for recovery playJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
PolyPid Ltd. Trading Near Value Zone — Recovery Ahead2025 Macro Impact & Consistent Return Strategy Ideas - kangso.co.kr
HC Wainwright Reaffirms “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - MSN
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
3.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):